Roivant and its subsidiary Priovant reported that Lisraya outperformed placebo in two Phase 3 studies for non-infectious uveitis, covering 371 patients. The results, coming shortly after Lisraya’s dermatomyositis approval, are designed to support an FDA label expansion targeting a larger inflammatory eye population. Roivant said it expects to file for expanded approval in the first half of 2027, indicating the company is turning its immune-modifying platform into a multi-indication franchise rather than a single-asset play. Analysts pointed to significant existing treatment coverage with TNF inhibitors as an addressable market for a differentiated mechanism. For development teams, the near-term emphasis will shift to regulatory dialogue and how efficacy and safety outcomes translate into differentiated positioning in uveitis treatment guidelines.